Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1980 Sep 1;152(3):657–673. doi: 10.1084/jem.152.3.657

Macrophages elicited with heat-killed bacillus Calomette-Guerin protect C57BL/6J mice against a syngeneic melanoma

PMCID: PMC2185920  PMID: 6997425

Abstract

We have demonstrated that a murine cytotoxic peritoneal cell can be elicited by intraperitoneal immunization with heat-killed Mycobacterium bovis, strain Bacillus Calmette-Guerin (BCG). When these cells are injected together with cells of clone B(5)59 of B16 melanoma in a Winn- type transfer assay into syngeneic C57BL/6J mice, the tumorigenic potential of the melanoma is completely abrogated. Similarly, mice immunized intraperitoneally with dead BCG are protected against intraperitoneal challenge with a number of B16 melanoma cells sufficient to cause tumors in 100% of control mice. However, mice immunized intraperitoneally with dead BCG are not protected against tumor formation when B16 melanoma cells are injected subcutaneously. Co- injection of BCG-elicited peritoneal cells with B16 melanoma cells into nude or sublethally irradiated (650 rad) mice inhibits tumor formation in > 85% of the mice, indicating that additional participation of host bone marrow- or thymus-derived leukocytes is not required to eradicate the tumor implant. The effector cell in the BCG-induced peritoneal exudate is adherent and phagocytic and is a mononuclear phagocyte. Nonadherent lymphoid cells from the same BCG-induced peritoneal exudate and from thioglycollate-broth-elicited granylocytes and macrophages neither prevent nor delay B16 tumor formation.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman L. C., Snyderman R., Oppenheim J. J., Mergenhagen S. E. A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. J Immunol. 1973 Mar;110(3):801–810. [PubMed] [Google Scholar]
  2. Anderson R. E., Warner N. L. Ionizing radiation and the immune response. Adv Immunol. 1976;24:215–335. doi: 10.1016/s0065-2776(08)60331-4. [DOI] [PubMed] [Google Scholar]
  3. Bartlett G. L., Purnell D. M., Kreider J. W. BCG inhibition of murine leudemia: local suppression and systemic tumor immunity require different doses. Science. 1976 Jan 23;191(4224):299–301. doi: 10.1126/science.1108198. [DOI] [PubMed] [Google Scholar]
  4. Bennett J. A., Rao V. S., Mitchell M. S. Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5142–5144. doi: 10.1073/pnas.75.10.5142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bianco C., Griffin F. M., Jr, Silverstein S. C. Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med. 1975 Jun 1;141(6):1278–1290. doi: 10.1084/jem.141.6.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bucana C., Hanna M. G., Jr Immunoelectronmicroscopic analysis of surface antigens common to Mycobacterium bovis (BCG) and tumor cells. J Natl Cancer Inst. 1974 Nov;53(5):1313–1323. doi: 10.1093/jnci/53.5.1313. [DOI] [PubMed] [Google Scholar]
  7. COHN Z. A., BENSON B. THE DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. MORPHOLOGY, CYTOCHEMISTRY, AND BIOCHEMISTRY. J Exp Med. 1965 Jan 1;121:153–170. doi: 10.1084/jem.121.1.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cleveland R. P., Meltzer M. S., Zbar B. Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst. 1974 Jun;52(6):1887–1895. doi: 10.1093/jnci/52.6.1887. [DOI] [PubMed] [Google Scholar]
  9. Cohn Z. A. Activation of mononuclear phagocytes: fact, fancy, and future. J Immunol. 1978 Sep;121(3):813–816. [PubMed] [Google Scholar]
  10. Edelson P. J., Erbs C. Biochemical and functional characteristics of the plasma membrane of macrophages from BCG-infected mice. J Immunol. 1978 May;120(5):1532–1536. [PubMed] [Google Scholar]
  11. Fidler I. J., Kataoka T., Hanna M. G., Jr A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs. Cancer Res. 1976 Dec;36(12):4459–4466. [PubMed] [Google Scholar]
  12. Griffin F. M., Jr, Bianco C., Silverstein S. C. Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G. J Exp Med. 1975 Jun 1;141(6):1269–1277. doi: 10.1084/jem.141.6.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hanna M. G., Jr, Zbar B., Rapp H. J. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst. 1972 May;48(5):1441–1455. [PubMed] [Google Scholar]
  14. Hanna M. G., Jr, Zbar B., Rapp H. J. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis., 2. Comparative effects of vaccinia virus, oxazolone, and turpentine. J Natl Cancer Inst. 1972 Jun;48(6):1697–1707. [PubMed] [Google Scholar]
  15. Herberman R. B., Djeu J., Kay H. D., Ortaldo J. R., Riccardi C., Bonnard G. D., Holden H. T., Fagnani R., Santoni A., Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. doi: 10.1111/j.1600-065x.1979.tb00267.x. [DOI] [PubMed] [Google Scholar]
  16. Hibbs J. B., Jr, Lambert L. H., Jr, Remington J. S. In vitro nonimmunologic destruction of cells with abnormal growth characteristics by adjuvant activated macrophages. Proc Soc Exp Biol Med. 1972 Mar;139(3):1049–1052. doi: 10.3181/00379727-139-36295. [DOI] [PubMed] [Google Scholar]
  17. Kiessling R., Wigzell H. An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev. 1979;44:165–208. doi: 10.1111/j.1600-065x.1979.tb00270.x. [DOI] [PubMed] [Google Scholar]
  18. Klimpel G. R., Okada M., Henney C. S. Inhibition of in vitro cytotoxic responses by BCG-induced macrophage-like suppressor cells. II. Suppression occurs at the level of a "helper" T cell. J Immunol. 1979 Jul;123(1):350–357. [PubMed] [Google Scholar]
  19. Meltzer M. S., Tucker R. W., Sanford K. K., Leonard E. J. Interaction of BCG-activated macrophages with neoplastic and nonneoplastic cell lines in vitro : quantitation of the cytotoxic reaction by release of tritiated thymidine from prelabeled target cells. J Natl Cancer Inst. 1975 May;54(5):1177–1184. doi: 10.1093/jnci/54.5.1177. [DOI] [PubMed] [Google Scholar]
  20. Michl J., Ohlbaum D. J., Silverstein S. C. 2-Deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages. I. Description of the inhibitory effect. J Exp Med. 1976 Dec 1;144(6):1465–1483. doi: 10.1084/jem.144.6.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Minden P., McClatchy J. K., Wainberg M., Weiss D. W. Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J Natl Cancer Inst. 1974 Nov;53(5):1325–1331. doi: 10.1093/jnci/53.5.1325. [DOI] [PubMed] [Google Scholar]
  22. Morahan P. S., Kaplan A. M. Macrophage activation and anti-tumor activity of biologic and synthetic agents. Int J Cancer. 1976 Jan 15;17(1):82–89. doi: 10.1002/ijc.2910170112. [DOI] [PubMed] [Google Scholar]
  23. Namba M., Ogura T., Hirao F., Azuma I., Yamamura Y. Antitumor activity of peritoneal exudate cells induced by cell-wall skeleton of Mycobacterium bovis BCG. Gan. 1978 Dec;69(6):831–834. [PubMed] [Google Scholar]
  24. Nathan C. F., Hill V. M., Terry W. D. Isolation of a subpopulation of adherent peritoneal cells with anti-tumour activity. Nature. 1976 Mar 11;260(5547):146–148. doi: 10.1038/260146a0. [DOI] [PubMed] [Google Scholar]
  25. Nathan C. F., Silverstein S. C., Brukner L. H., Cohn Z. A. Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med. 1979 Jan 1;149(1):100–113. doi: 10.1084/jem.149.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nathan C. F., Terry W. D. Decreased phagocytosis by peritoneal macrophages from BCG-treated mice: induction of the phagocytic defect in normal macrophages with BCG in vitro. Cell Immunol. 1977 Mar 15;29(2):295–311. doi: 10.1016/0008-8749(77)90324-0. [DOI] [PubMed] [Google Scholar]
  27. North R. J. Cellular kinetics associated with the development of acquired cellular resistance. J Exp Med. 1969 Aug 1;130(2):299–314. doi: 10.1084/jem.130.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. North R. J. The concept of the activated macrophage. J Immunol. 1978 Sep;121(3):806–809. [PMC free article] [PubMed] [Google Scholar]
  29. Reinherz E. L., Moretta L., Roper M., Breard J. M., Mingari M. C., Cooper M. D., Schlossman S. F. Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. A comparison. J Exp Med. 1980 Apr 1;151(4):969–974. doi: 10.1084/jem.151.4.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Saksela E., Timonen T., Ranki A., Häyry P. Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets. Immunol Rev. 1979;44:71–123. doi: 10.1111/j.1600-065x.1979.tb00268.x. [DOI] [PubMed] [Google Scholar]
  31. Silagi S., Bruce S. A. Suppression of malignancy and differentiation in melanotic melanoma cells. Proc Natl Acad Sci U S A. 1970 May;66(1):72–78. doi: 10.1073/pnas.66.1.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Silagi S. Control of pigment production in mouse melanoma cells in vitro. Evocation and maintenance. J Cell Biol. 1969 Nov;43(2):263–274. doi: 10.1083/jcb.43.2.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Silagi S. Modification of malignancy by 5-bromodeoxyuridine. Studies of reversibility and immunological effects. In Vitro. 1971 Sep-Oct;7(2):105–114. doi: 10.1007/BF02628269. [DOI] [PubMed] [Google Scholar]
  34. Snyderman R., Pike M. C. An inhibitor of macrophage chemotaxis produced by neoplasms. Science. 1976 Apr 23;192(4237):370–372. doi: 10.1126/science.946556. [DOI] [PubMed] [Google Scholar]
  35. Steinman R. M., Cohn Z. A. The interaction of particulate horseradish peroxidase (HRP)-anti HRP immune complexes with mouse peritoneal macrophages in vitro. J Cell Biol. 1972 Dec;55(3):616–634. doi: 10.1083/jcb.55.3.616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. WINN H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol. 1961 Feb;86:228–239. [PubMed] [Google Scholar]
  37. Wolfe S. A., Tracey D. E., Henney C. S. BCG-induced murine effector cells. II. Characterization of natural killer cells in peritoneal exudates. J Immunol. 1977 Sep;119(3):1152–1158. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES